Prosus NV News - PRX | Aktien Euronext

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2009 Results on February 24, 2010

WOODCLIFF LAKE, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE:PRX) announced today that it will host a...

MonoSol Rx and Strativa Pharmaceuticals Extend Strategic Relationship

Option to collaborate on three new products Relationship built on successful development of ondansetron oral soluble film currently under FDA...

Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER

Par to Begin Shipping Tramadol ER Immediately WOODCLIFF LAKE, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc...

Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009

Achieves Record Quarterly Gross Margin of $92 Million WOODCLIFF LAKE, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc...

Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)

Par to Begin Shipping Nateglinide Immediately WOODCLIFF LAKE, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc...

Par Pharmaceutical Reports EPS of $0.71 for Second Quarter 2009

Brand & Generic Business Units Drive Strong Earnings WOODCLIFF LAKE, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc...

Par Pharmaceutical to Host Second Quarter 2009 Earnings Conference Call on August 4 at 9:00 am

WOODCLIFF LAKE, N.J., July 15 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE:PRX) announced today that it will host a...

MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip

WARREN, N.J., April 9 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in...

MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA

Expects to File NDA with FDA in Early to Mid-2009 WARREN, N.J., Dec. 2 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and...

/C O R R E C T I O N -- Par Pharmaceutical Companies, Inc./

In the news release, Patrick G. LePore Elected to Board of Directors of Par Pharmaceutical Companies, Inc., issued earlier today by Par...

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Prosus NV (PRX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

PRX Nachrichten

Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2009 Results on February 24, 2010

MonoSol Rx and Strativa Pharmaceuticals Extend Strategic Relationship

Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER

Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009

Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)

Par Pharmaceutical Reports EPS of $0.71 for Second Quarter 2009

Par Pharmaceutical to Host Second Quarter 2009 Earnings Conference Call on August 4 at 9:00 am

MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip

MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA

/C O R R E C T I O N -- Par Pharmaceutical Companies, Inc./

PRX Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Prosus NV (PRX) News

Prosus NV (PRX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

PRX Nachrichten

Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2009 Results on February 24, 2010

MonoSol Rx and Strativa Pharmaceuticals Extend Strategic Relationship

Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER

Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009

Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)

Par Pharmaceutical Reports EPS of $0.71 for Second Quarter 2009

Par Pharmaceutical to Host Second Quarter 2009 Earnings Conference Call on August 4 at 9:00 am

MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip

MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA

/C O R R E C T I O N -- Par Pharmaceutical Companies, Inc./

PRX Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen